Skip to Content

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

The combination of abemaciclib and trastuzumab improved survival rates in women with HR+, HER2+ advanced breast cancer compared to chemotherapy plus trastuzumab, with a manageable safety profile.

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top